Polly Roy

Prof. Polly Roy

London School of Hygiene and Tropical Medicine
orcid

Research Focus & Metrics

Academic Career Length

56Years (1971-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2003 in Nature
Verified
Journal Article
Closed access
PDF file
SDSandra S. Diebold
Sandra S. Diebold
MMMaria Montoya
Maria Montoya
HUHermann Unger
Hermann Unger
LALena Alexopoulou
Lena Alexopoulou
Polly RoyPolly Roy
Polly Roy
CSCaetano Reis e Sousa
Caetano Reis e Sousa

1 September 2003 in Trends in Microbiology
Verified
Journal Article
Closed access
RNRob Noad
Rob Noad
Polly RoyPolly Roy
Polly Roy

1 February 2021 in The Lancet
Verified
Journal Article
Closed access
IJIan Jones
Ian Jones
Polly RoyPolly Roy
Polly Roy

18 September 2004 in FEBS Letters
Verified
Journal Article
Open access
EMEduardo Mortola
Eduardo Mortola
Polly RoyPolly Roy
Polly Roy
Virus‐like particles (VLPs) produced by recombinant expression of the major viral structural proteins could be an attractive method for severe acute respiratory syndrome (SARS) control. In this study, using the baculovirus system, we generated recombinant viruses that expressed S, E, M and N structural proteins of SARS‐CoV either individually or simultaneously. The expression level, size and authenticity of each recombinant SARS‐CoV protein were determined. In addition, immunofluorescence and FACS analysis confirmed the cell surface expression of the S protein. Co‐infections of insect cells with two recombinant viruses demonstrated that M and E could assemble readily to form smooth surfaced VLPs. On the other hand, simultaneous high level expression of S, E and M by a single recombinant virus allowed the very efficient assembly and release of VLPs. These data demonstrate that the VLPs are morphological mimics of virion particles. The high level expression of VLPs with correct S protein conformation by a single recombinant baculovirus offers a potential candidate vaccine for SARS.

1 September 2008 in Journal of Virology
Verified
Journal Article
Open access
PDF file
MBMark Boyce
Mark Boyce
CCCristina C. P. Celma
Cristina C. P. Celma
Polly RoyPolly Roy
Polly Roy
Bluetongue virus (BTV), an insect-vectored emerging pathogen of both wild ruminants and livestock, has had a severe economic impact in agriculture in many parts of the world. The investigation of BTV replication and pathogenesis has been hampered by the lack of a reverse genetics system. Recovery of infectious BTV is possible by the transfection of permissive cells with the complete set of 10 purified viral mRNAs derived in vitro from transcribing cores (M. Boyce and P. Roy, J. Virol. 81:2179-2186, 2007). Here, we report that in vitro synthesized T7 transcripts, derived from cDNA clones, can be introduced into the genome of BTV using a mixture of T7 transcripts and core-derived mRNAs. The replacement of genome segment 10 and the simultaneous replacement of segments 2 and 5 encoding the two immunologically important outer capsid proteins, VP2 and VP5, are described. Further, we demonstrate the recovery of infectious BTV entirely from T7 transcripts, proving that synthetic transcripts synthesized in the presence of cap analogue can functionally substitute for viral transcripts at all stages of the BTV replication cycle. The generation of BTV with a fully defined genome permits the recovery of mutations in a defined genetic background. The ability to generate specific mutants provides a new tool to investigate the BTV replication cycle as well as permitting the generation of designer vaccine strains, which are greatly needed in many countries.

1 December 1995 in Nature
Verified
Journal Article
Closed access
PDF file
ZRZihe Rao
Zihe Rao
ABAlexander S. Belyaev
Alexander S. Belyaev
EFElizabeth Fry
Elizabeth Fry
Polly RoyPolly Roy
Polly Roy
IJIan M. Jones
Ian M. Jones
DSDavid Ian Stuart
David Ian Stuart